The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint.

INSERM (French National Institute of Health and Medical Research), U558, F-31073 Toulouse, France.
Neurology (Impact Factor: 8.3). 12/2006; 67(9 Suppl 3):S6-11. DOI: 10.1212/WNL.67.9_suppl_3.S6
Source: PubMed

ABSTRACT Preventive approaches in the field of Alzheimer disease (AD) is important but these trials raise many questions. Which protective factor should be studied? What population should be studied? With which principal and secondary criteria? We present here the design of the ongoing GuidAge Study. In the past, several studies suggest that Ginkgo biloba could have a potential benefit effect on cognitive function. The aim of the GuidAge Study is to evaluate the efficacy of 240 mg/d of EGb 761 in the prevention of AD.
GuidAge is a 5-year double-blind randomized trial conducted in France by a private practice/hospital network of general practitioners and hospital practitioners specializing in memory disorders. This study enrolled elderly subjects with spontaneous memory complaint and the primary outcome is the incidence of AD during a 5 years follow-up period. A total of 2854 subjects were enrolled between March 2002 and September 2004. The age of the study population was 76.8 +/- 4.4 with mean MMSE at entry 27.8 +/- 1.7.
The GuidAge study is the largest study carried out in Europe on the prevention of AD. Final results should be available in 2010.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Subjective cognitive complaints (SCCs) are being increasingly recognized as a preclinical phase of dementia. Thus, SCCs may represent a "promising" stage for planning and implementing preventive interventions aimed at reducing the incidence of cognitive disorders. The aim of the present study is to present and discuss the available evidence coming from clinical trials adopting cognitive interventions in individuals with SCCs. A systematic review of literature was conducted to evaluate the available trials testing nonpharmacological cognitive interventions for the prevention of dementia in subjects with SCCs. Six studies were included in the present study. Overall, most interventions showed to objectively improve cognitive performance in subjects with SCCs. A relevant heterogeneity was found concerning their characteristics and feasibility. Conversely, there is a current lack of evidence in the literature about the efficacy of nonpharmacological cognitive interventions for preventing dementia or cognitive impairment.
    American Journal of Alzheimer s Disease and Other Dementias 07/2013; 28(6). DOI:10.1177/1533317513494441 · 1.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To quantify the ability of a marker to predict the onset of a clinical outcome in the future, time-dependent estimators of sensitivity, specificity, and ROC curve have been proposed accounting for censoring of the outcome. In this paper, we review these estimators, recall their assumptions about the censoring mechanism and highlight their relationships and properties. A simulation study shows that marker-dependent censoring can lead to important biases for the ROC estimators not adapted to this case. A slight modification of the inverse probability of censoring weighting estimators proposed by Uno et al. (2007) and Hung and Chiang (2010a) performs as well as the nearest neighbor estimator of Heagerty et al. (2000) in the simulation study and has interesting practical properties. Finally, the estimators were used to evaluate abilities of a marker combining age and a cognitive test to predict dementia in the elderly. Data were obtained from the French PAQUID cohort. The censoring appears clearly marker-dependent leading to appreciable differences between ROC curves estimated with the different methods.
    Biometrical Journal 09/2013; 55(5). DOI:10.1002/bimj.201200045 · 1.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acetylcholinesterase (AChE) is a key target in the treatment of Alzheimer's disease (AD). We studied the potential anti-AChE activities of Acacia nilotica (Leguminosae) and Rhamnus prinoides (Rhamnaceae) plants that have previously been shown to affect central nervous system activities. Sonicated aqueous extracts of A. nilotica and R. prinoides displayed significant AChE inhibition by about 56 and 53%, respectively, after 5 min incubation at 0.1mg/ml final assay concentration. Inhibition kinetics showed both plant preparations to be mixed inhibitors (specifically non-competitive uncompetitive type). Galanthamine was assayed as a positive control and was found to be a very potent mixed type (competitive non-competitive) inhibitor; IC50 of 0.0004 mg/ml compared to 0.079 mg/ml for A. nilotica and 0.201 mg/ml for R. prinoides. We conclude that although the AChE inhibition by A. nilotica and R. prinoides is not as potent as that of galanthamine, in addition to their known antioxidant and anti-inflammatory activities these plants could provide novel poly-pharmacological leads of potential benefit to the treatment of AD and therefore warrant further investigation.